Clinical Trial Update: A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating glycemic control with glimepiride versus rimonabant added to metformin in Type 2 diabetes was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Acomplia (rimonabant)
• Amaryl (glimepiride)
• metformin (metformin)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: TERMINATED